Edgewise Therapeutics
EWTX
177 hedge funds and large institutions have $2.71B invested in Edgewise Therapeutics in 2024 Q3 according to their latest regulatory filings, with 52 funds opening new positions, 58 increasing their positions, 44 reducing their positions, and 15 closing their positions.
349% more call options, than puts
Call options by funds: $60M | Put options by funds: $13.3M
247% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 15
48% more capital invested
Capital invested by funds: $1.83B → $2.71B (+$875M)
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
32% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 44
26% more funds holding
Funds holding: 140 → 177 (+37)
0.69% less ownership
Funds ownership: 108.8% → 108.11% (-0.69%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$39M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$38.8M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$19.9M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$18.2M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$13.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$82.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$36M |
| 3 |
Goldman Sachs
New York
|
-$22.7M |
| 4 |
DM
Deerfield Management
New York
|
-$21.8M |
| 5 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$17.9M |
EWTX Hedge Fund Activity: Q3 2024 in Review
177 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q3 2024, worth a combined $2.71B — up 48% from $1.83B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new EWTX positions and 15 closed out — a net gain of 37 holders — while 58 added to existing stakes and 44 trimmed.
The largest buyer was Braidwell, opening a new position worth an estimated $39M. The largest seller was Fidelity Investments, cutting an estimated $82.1M.
- 177 institutional investors held Edgewise Therapeutics (EWTX) as of Q3 2024, up from 140 in Q2 2024.
- Funds reported $2.71B of Edgewise Therapeutics stock for Q3 2024, up 48% quarter-over-quarter.
- 52 funds opened new Edgewise Therapeutics positions in Q3 2024 and 15 closed out, a net change of +37 holders.
- The largest Edgewise Therapeutics buyer in Q3 2024 was Braidwell, an estimated $39M added.
- The largest Edgewise Therapeutics seller in Q3 2024 was Fidelity Investments, an estimated $82.1M sold.
Based on aggregated 13F filings for Q3 2024.